INT6625
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
In addition they can result in over-suppression of parathyroid hormone (PTH), adynamic bone, and are associated with both soft tissue and vascular calcification (Goodman et al 2000; Goodman 2001). | |||||||||||||||
| |||||||||||||||
|
In addition they can result in over-suppression of parathyroid hormone (PTH), adynamic bone, and are associated with both soft tissue and vascular calcification (Goodman et al 2000; Goodman 2001). | |||||||||||||||
| |||||||||||||||
|
The other aminopyridine 2A-7 (3 X 10(-5) - 3 X 10(-4) M) caused suppression of the compound action potential, a diminished propagation velocity and a reduction of the PTH, an action also observed with lidocaine. | |||||||||||||||
| |||||||||||||||
|
Patients in the exemestane group had a significant decrease in BMD and early parathyroid hormone (at month 6) and an increase in bone alkaline phosphatase (B-ALP) and the carboxy-terminal telopeptide of type I collagen after 24 months. | |||||||||||||||
| |||||||||||||||
|
Treatment reduced inappropriately elevated parathyroid hormone levels, presumably caused by long-term bisphosphonate use. | |||||||||||||||
| |||||||||||||||
|
A small but statistically significant increase in serum calcium was seen, as was a significant decrease in serum parathyroid hormone. | |||||||||||||||
| |||||||||||||||
|
Systemic factors such as oestrogen deprivation and parathyroid hormone strongly activate remodelling and can, in several circumstances, lead to imbalances in the remodelling cycle. | |||||||||||||||
| |||||||||||||||
|
Treatment with a new calcimimetic agent, cinacalcet HCl (Mimpara, Amgen, Munich, Germany), resulted in a rapid decline in elevated parathyroid hormone levels, near normalization of other laboratory markers of bone metabolism, improvement in mobility and skeletal pain caused by renal osteodystrophy, and an increase in body weight. | |||||||||||||||
| |||||||||||||||
|
Although immunotherapy produced a partial response, it failed to decrease serum parathyroid hormone to the levels recommended by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative clinical practice guidelines. | |||||||||||||||
| |||||||||||||||
|
Like calcitriol, paricalcitol suppresses pre-pro-PTH mRNA synthesis and has a prolonged effect of PTH inhibition beyond its mean half-life of approximately 14 hours in hemodialysis patients (Cato et al 1998; Brandi et al 2002; Staniforth et al 2005). | |||||||||||||||
| |||||||||||||||
|
Randomized trials have been conducted showing that paricalcitol capsules demonstrate effective suppression of PTH, achieving ? | |||||||||||||||
| |||||||||||||||
|
Indirect comparison of these results suggests paricalcitol effectively suppressed PTH with smaller alterations in serum calcium and phosphorus.
| |||||||||||||||
| |||||||||||||||
|
A study in CKD patients showed that oral calcitriol suppressed baseline PTH levels by 25% over 1 year of treatment, but at doses between 0.25 mcg/day and 1 mcg/day, calcitriol led to hypercalcemia in 64% of patients in the trial and a 139% increase in urinary calcium excretion after 1 year (Calcitriol new drug application [NDA] 18-044 FDA). | |||||||||||||||
| |||||||||||||||
|
In comparison, paricalcitol capsules had a mean PTH suppression of 42% with only 2% of patients in the paricalcitol groups experiencing hypercalcemia (Coyne et al 2006). | |||||||||||||||
| |||||||||||||||
|
Although the oral administration of alfacalcidol showed no effects, 3 weeks of intermittent intravenous injection of maxacalcitol therapy decreased the serum intact PTH concentration from 597 pg/ml to 40 pg/ml, and the bone pain was greatly relieved. | |||||||||||||||
| |||||||||||||||
|
The median decrease in PTH values from baseline was 88% (range, 33-99%). | |||||||||||||||
| |||||||||||||||
|
In conclusion, the subtotal parathyroidectomy or total parathyroidectomy with autotransplantation cause a rapid decrease of PTH level and the improvement of the clinical symptoms in patients with medical treatment resistant secondary hyperparathyroidism. | |||||||||||||||
| |||||||||||||||
|
We have noted a relationship between major involutive phenomena and a major reduction in iPTH and Ca serum levels, suggesting that a lower dose of cinacalcet may have been used. | |||||||||||||||
| |||||||||||||||
|
Our treatment reducing PTH levels resulted in a marked relief from pruritus and other symptoms, suggesting that patients in this condition, before undergoing surgical parathyroidectomy, may be usefully treated with this therapeutic modality. | |||||||||||||||
| |||||||||||||||
|
CONCLUSION: A rapid decrease in serum parathyroid hormone level after parathyroidectomy appears to suppress bone resorption, as well as cause a transient marked increase in bone formation and an increase in normal lamellar osteoid seams.
| |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.